Home > News > The Blanking Period Following Pulmonary Vein Isolation – Relevance and Duration
Atrial Fibrillation
Read Time: 7 mins

The Blanking Period Following Pulmonary Vein Isolation – Relevance and Duration

Published Online: May 18th 2016 European Journal of Arrhythmia & Electrophysiology, 2016;2(1):26–9 DOI: http://doi.org/10.17925/EJAE.2016.02.01.26
Authors: Moloy Das, Dhiraj Gupta
Quick Links:
Article Information

Early recurrences of atrial tachyarrhythmia (ERAT) commonly occur in the initial months following catheter ablation of atrial fibrillation. Patients with ERAT are at increased risk of later recurrence, but the presence of ERAT does not necessarily indicate longer-term procedural failure. International consensus guidelines accordingly recommend a three-month ‘blanking period’. Such ERAT episodes may be related to post-ablation pro-arrhythmic factors, such as inflammation, autonomic dysregulation and lesion maturation. However, studies suggest that these transient factors have a limited duration and ERAT occurring beyond this point may be more predictive of both pulmonary vein reconnection and further recurrence. This review examines the need for a blanking period and its most appropriate duration.


Atrial fibrillation, catheter ablation, pulmonary vein isolation, blanking period, AF recurrence


Catheter ablation has been consistently shown to provide improved freedom from atrial fibrillation (AF) compared to medical management but, nevertheless, success rates following a single procedure remain relatively poor and are significantly lower than those for ablation procedures for most other supraventricular arrhythmias.1,2Recurrence of atrial tachyarrhythmias (AT; comprising AF, atrial flutter or atrial tachycardia), either symptomatic or asymptomatic, has been reported to occur in more than one in two patients in long-term follow-up after ablation.3,4Outcomes for paroxysmal AF are better than for persistent AF,5and although success rates have gradually increased as procedural techniques have evolved, even in contemporary studies of paroxysmal AF patients ablated using radiofrequency energy, freedom from AF at 1-year follow-up after a single procedure has only approached 70%.6These disappointing success rates may contribute towards the difficulty in establishing clear prognostic benefits, such as stroke-reduction, of catheter ablation over medical therapy.

Recurrence of AT can occur at any time following catheter ablation of AF. While the majority occur in the first 6 months after ablation, first recurrences have been seen more than 4 years later.4AT recurrence in the immediate aftermath of left atrial ablation is particularly common,7–9and the frequency and extent of episodes can exceed those experienced prior to ablation in around 15% of patients.10However, there remains some debate over the true relevance of such recurrences in the immediate period following AF ablation.

Early recurrence of atrial tachyarrhythmia
It has long been recognised that early recurrences of AT (ERAT) occurring soon after radiofrequency ablation may not necessarily portend longer-term arrhythmia recurrence,10,11 with up to 60% of patients experiencing ERAT going on to have a successful outcome in the longer-term.12 Accordingly, international consensus guidelines recommend a 3-month ‘blanking period’ following AF ablation during which AT recurrences “should not be classified as treatment failure”.12However, data have also shown that individuals with ERAT have lower long-term success rates than those without early recurrence,7,13–16and that patients with ERAT who undergo early re-ablation have improved freedom from AT at 12 months,17,18suggesting that ERAT may be of clinical relevance.

The mechanisms leading to ERAT following radiofrequency ablation are not fully understood but are commonly attributed to a number of transient pro-arrhythmic factors. These include: post-ablation inflammation,19,20 temporary autonomic imbalance21,22or the time taken for the lesion set deployed to mature.23 Whilst pulmonary vein (PV) reconnection has been shown to be associated with long-term arrhythmia recurrence in paroxysmal AF,24–26these transient factors would not be expected to lead to late AT recurrence. However, the time point at which these transient causes of ERAT give way to arrhythmia episodes related to PV reconnection has not been clearly established.

Post-ablation inflammation

Inflammation has been identified as an important cause for the initiation and maintenance of AF, including after major inflammatory insults such as cardiac surgery.20,27 Radiofrequency catheter ablation of cardiac tissue also stimulates a strong inflammatory response, with histological examination demonstrating infiltration of inflammatory cells into the ablated area and measurement of serum markers of inflammation showing an increase following ablation.19,28,29As the time-course of the inflammatory phase following AF ablation was unclear, a recent study set out to determine this using serum markers of inflammation and myocardial injury.30Lim and colleagues serially tested 90 patients undergoing radiofrequency AF ablation at baseline and at 1 day, 2 days, 3 days, 7 days and 1 month after ablation for serum levels of high-sensitivity C-reactive protein, Troponin T, creatine kinase-MB, as well as white cell and neutrophil counts. The authors found that the inflammatory markers (high-sensitivity C-reactive protein, white cell count and neutrophil count) all peaked by 3 days post-ablation, remained elevated compared to baseline at 7 days, but had returned to baseline levels by 1 month. For markers of myocardial injury (Troponin T and creatine kinase-MB), a peak was seen at day one post-ablation, with a return to baseline by day seven. Ablation time was identified as an independent predictor of Troponin T release, in keeping with previous studies.29,31They also sought to determine the time-course of the pro-thrombotic state following AF ablation using measurement of fibrinogen and D-Dimer, and found that these markers peaked at seven days post-ablation, and although fibrinogen had returned to baseline by 1 month, D-Dimer levels remained slightly elevated at this time point.

While it should be acknowledged that serum inflammatory markers may not have the required sensitivity to detect subtle persisting inflammation, these data suggest that the inflammatory phase following AF ablation resolves within the first month. Of note, the extent to which high-sensitivity C-reactive protein was raised was the only independent predictor of ERAT in the first few days after ablation, but none of the markers of inflammation or myocardial injury were predictive of postblanking period AT recurrence.

Autonomic imbalance
Autonomic dysregulation can be a potential trigger for AF and has therefore been mooted as a potential ablation target. 21,32–36However, even in the absence of specific targeting of autonomic ganglionated plexi, the autonomic nervous system is known to be affected by standard pulmonary vein isolation (PVI) ablation. Hsieh et al. examined heart rate variability changes in 37 patients with paroxysmal AF, 30 of whom underwent a PVI procedure and seven of whom had a transseptal puncture performed but no ablation.22 Heart rate variability measures included time-domain (standard deviation of RR intervals and root-mean-square of differences of adjacent RR intervals) and frequency-domain (low frequency, high frequency, and low-frequency/ high-frequency ratio) parameters, and were obtained pre-ablation and 1 week, 1 month and 6 months after ablation. The authors found a significant decrease in measures of sympathetic and, particularly, parasympathetic activity, with a corresponding increase in the mean sinus rate, 1 week after ablation in patients who underwent PVI. However, these changes had resolved back to baseline by one month post-ablation. There were no changes in heart rate variability parameters in the patients who underwent transseptal puncture but no left atrial ablation. This study of the time-course of autonomic dysfunction therefore suggests that this phase resolves within 1 month.

Maturation of ablation lesions
The time-course of maturation of ablation lesions has been studied in animal models through pathological examination at various time-points after ablation. Huang and co-workers performed catheter ablation in the ventricles of dogs and undertook pathological examinations of the ablated areas 4–5 days later.37This showed that the lesions had a well-demarcated margin, and microscopic examination demonstrated “circumscribed areas of coagulation necrosis with a peripheral zone of cellular infiltration.” Similarly, a study by Wittkampf and colleagues in another canine model identified homogeneous lesions with a distinct margin after 7 days.38Collectively, these data suggest that ablation lesions mature to their fully-developed state within approximately 1 week.

Rationale for and duration of the ‘blanking period’

From the studies described above, there are compelling reasons for the application of a blanking period. Recurrence of arrhythmia due to any of these transient factors should not lead to later recurrence, and it is therefore appropriate not to deem ERAT occurring during the time-course of these factors to be clinically relevant as this ensures that unnecessary re-interventions are avoided. Current international consensus guidelines recommend a 3-month blanking period,12and the rationale for this duration is based on clinical studies of the relationship between recurrence within the first 3 months and subsequent recurrence. Although such studies have shown that a significantly greater proportion of patients with ERAT in the first 3 months post-PVI go on to have later recurrence compared those without ERAT,7,13,15,16the main concern regarding taking ERAT to signify later recurrence has been the poor positive predictive value of this finding. An early study by O’Donnell et al. utilising a 3-month blanking period found that 38.5% of patients experiencing ERAT were free of later recurrence.11Subsequently, a number of further studies have examined this relationship, with some finding a similar proportion in the range of 32–39%,8,13,39 others identifying a higher proportion in the range of 43–49%,7,14,40and one study demonstrating a rate of 58.9%.41Overall, therefore, these studies have shown that up to 60% of patients with ERAT in the first 3 months post-ablation do not experience further AT recurrence during post-blanking period follow-up, and the authors of the consensus statement have accordingly deemed 3 months to be the most appropriate duration for the blanking period.12However, given that some early episodes of AT post-PVI are likely to be related to transient pro-arrhythmic factors that do not cause later recurrence, this is to be expected. The primary issue, therefore, is not whether the blanking period should exist at all, but rather how long it should be.

Timing of ERAT within the blanking period and relationship with late recurrence
While several studies have examined the overall relationship between ERAT and later AT recurrence, relatively few have explored the relevance of the timing of these occurrences within the blanking period. One study that did do this, by Themistoclakis et al., included 1,298 patients undergoing PVI and classified patients with ERAT by the month of the first occurrence.7Ablation was performed using point-by-point radiofrequency energy application, and antiarrhythmic drugs were stopped immediately in paroxysmal AF patients and after 2 months in those with persistent AF. The proportion of patients going on to suffer post-blanking period recurrences was 44% if the first episode of ERAT was in month one, 69% if in month two and 98% if in month three, indicating a high likelihood of later recurrence if ERAT began in months two or three.

A further study, by Bertaglia et al., again following point-by-point radiofrequency ablation and with antiarrhythmic drugs continued for at least 7 months, found that the rate of late recurrence was significantly higher in those with a first recurrence in month two or three (80%) compared to first ERAT in month one (56.7%).14As with the study by Themistoclakis et al., the main focus was on the timing of the first recurrence, rather than the time period in which ERAT episodes persisted. As it is entirely conceivable that an individual might have ERAT related to transient pro-arrhythmic factors in the first month post-ablation followed by ERAT related to PV reconnection in month two onwards, the timing of the last episode of ERAT would seem to be more valuable than that of the first episode. Added to this is the fact that the incidence of first AT recurrences is known to be highest in the first month, with diminishing levels in months two and three,7,8,14making analysis of outcomes for these small numbers of patients difficult.

There are only three studies that have provided data regarding timing of ERAT episodes regardless of whether this was the initial episode or a subsequent recurrence. In a re-analysis of data from Bertaglia et al.,29patients had on-going ERAT in months two to three having had their first episode in month one, and five patients had their first ERAT episode in months two to three.14Of these 34 patients with ERAT in months two to three (regardless of the timing of the first episode), 30 (88%) went on to have AT recurrence beyond the blanking period, compared to 11 of 109 (10%) patients without month two to three ERAT (p<0.0001). In contrast, a study by Joshi et al. using external loop recorders for automatic detection of AF recurrences in the first 3 months following point-bypoint radiofrequency ablation (divided into 2-week time periods) did not show AT recurrence in each 2-week period to be predictive of post-blanking AT recurrence up to 12 months post-PVI in a multivariate model.8However, specific data on the proportion of patients with AT recurrence in each 2-week period that went on to suffer post-blanking AF was not presented and therefore cannot be analysed further. As the study only comprised a total of 72 patients and utilised narrow timeperiods, such that only between 22% (n=16) and 54% (n=39) of subjects experienced ERAT within each time-period, the study may well have been underpowered to detect a difference between groups. In this study, antiarrhythmic drugs had been continued for at least 1 month and until complete freedom from AF was achieved.

More recently, a larger study of 300 AF patients undergoing point-by- point radiofrequency ablation was conducted by Liang and coworkers. 42Antiarrhythmic drugs were discontinued after 6 weeks in paroxysmal AF patients and after 3–6 months in those with persistent AF. In this study of the first 6 weeks following ablation, ERAT episodes were classified into ‘early’ (weeks one to two), ‘intermediate’ (weeks three to four) and ‘late’ (weeks five to six). The authors found that ERAT at any time in this 6-week period was predictive of treatment failure, but particularly if there were multiple episodes extending into the ‘late’ period. A re-analysis of these data shows that 50 of 59 (85%) patients with ERAT in weeks five to six went on to have later recurrence, compared to 82 of 241 (34%) patients with either no ERAT or ERAT confined to the first 4 weeks (p<0.0001). It should be noted that there was significant variation in the duration of antiarrhythmic drug therapy given after ablation between studies, which could impact upon the incidence of ERAT. Nevertheless, the findings of Liang et al. are similar to those of Bertaglia et al., and imply that recurrences that occur beyond the first 4 weeks after point-by-point radiofrequency ablation are clinically relevant.

Other energy sources and lesion sets

While the above studies have all reported on ERAT following point-bypoint radiofrequency ablation, there are also data on ERAT following cryothermal PVI. A sub-study of the Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation (STOP-AF) trial demonstrated that ERAT during the first 3 months after cryoballoon PVI was significantly related to later recurrence.43However, further details of the timing of ERAT episodes were not provided. Furthermore, the mechanism of tissue injury is markedly different for cryoablation, with creation of more homogeneous and clearly-defined lesions, as compared to the greater tissue necrosis and coagulation seen with radiofrequency energy.44,45The role and duration of inflammation following cryoballoon PVI may therefore differ to radiofrequency ablation,46,47and data pertaining to transient pro-arrhythmic factors following radiofrequency ablation cannot be assumed to be relevant to other energy sources.

The application of additional lesion sets may also impact upon ERAT. Incomplete linear lesions are prone to creating the substrate for macro re-entrant arrhythmias, and these may manifest at an early stage. A sub-study of the STAR-AF trial demonstrated that the rate of ERAT was highest with complex fractionated atrial electrogram ablation as sole strategy, followed by PVI alone, with the lowest rate seen with a combined approach.15The reasons for this are not entirely clear, and it may have been expected that more extensive ablation would lead to greater inflammation and ERAT. However, in the STAR-AF study, the combined approach resulted in superior outcomes compared to the individual strategies,39and since a 3-month blanking period was applied, the lower rate of ERAT may simply reflect the improved success in that arm.

Relationship between ERAT and PV reconnection
While the studies detailed above have studied the relationship between ERAT and late recurrence, we have recently published an investigation into the relationship between ERAT and PV reconnection,48which has been clearly established as being associated with long-term arrhythmia recurrence in paroxysmal AF.24–26In this study, 40 patients with paroxysmal AF underwent a protocol-mandated repeat electrophysiology study 2 months after point-by-point radiofrequency PVI, regardless of symptoms. Antiarrhythmic drugs were discontinued 4 weeks after the initial ablation. In the intervening period between the two procedures, patients were instructed to self-record a 30-second ECG each day, with additional recordings whenever they experienced symptoms, using a validated handheld ECG monitoring device.49Recordings were divided into those taken during the first 4 weeks (“month 1”) post-PVI, and those recorded from day 29 to the date of the repeat electrophysiology study (“month 2”).

ERAT was documented in 17 (42%) patients and PV reconnection was identified at repeat electrophysiology study in 25 (62%) patients, affecting a total of 41 (26%) PVs. ERAT either starting or continuing in month 2 was strongly associated with PV reconnection whereas ERAT limited to month 1 was not (85% versus 0%, p=0.006). In particular, month 2 ERAT was strongly associated with extensive PV reconnection (2 or more PVs) when compared to its absence (77% versus 11%, p<0.0001). These data, combined with the clinical recurrence data described above, are consistent with the notion that transient proarrhythmic factors resolve within the first month after ablation.

Clinical implications

These data suggest that the true blanking period following radiofrequency PVI should be 1 month rather than 3, which would have significant implications for clinical practice. Currently, AF recurrence in the second and third months post-procedure are recommended to be treated as “non-clinical” and should not prompt repeat ablation.12 However, shortening of the blanking period would allow earlier re-intervention, a strategy that has previously been shown to improve outcomes for patients with ERAT. Lellouche and co-workers demonstrated a reduction in later AF recurrence in those with ERAT from 91% to 51% with early re-intervention,17while Pokushalov et al. found that 80% of patients with ERAT had no later recurrence with a strategy of early re-ablation if triggers were seen (or antiarrhythmic drugs if no triggers were identified) compared to 33% without these interventions.18Although using a different treatment modality, a similar finding has also been shown for patients with ERAT following cryoballoon therapy.43Early re-intervention may therefore reduce subsequent AF recurrence and thereby minimise some of the impact on quality-of-life associated with this.50,51However, while the great majority of patients with ERAT beyond one month post-PVI appear to go on have later recurrence (>85% from available data), there remains a minority in whom their arrhythmia subsequently settles. As suggested by a study by Liang et al.,42it may be that careful monitoring of both the timing and frequency of ERAT episodes can help identify those most likely to benefit from early re-intervention.

The rationale for a blanking period following radiofrequency PVI is based on the presence of several transient pro-arrhythmic factors immediately following ablation and the fact that a significant proportion of patients with ERAT do not go on to develop late recurrence. However, these transient factors seem to resolve within 1 month, and studies of the timing of ERAT suggest that its occurrence beyond one month is strongly related to both late recurrence and more extensive PV reconnection. It may therefore be that the true blanking period following PVI is 1 month rather than 3 months.

Article Information:

Dhiraj Gupta has received speaker fees, research grants and Fellowship support from Biosense Webster, Inc. Moloy Das has nothing to declare in relation to this article. No funding was received in the publication of this article.


Dhiraj Gupta, Department of Cardiology, Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool, L14 3PE, UK. E: dhiraj.gupta@lhch.nhs.uk

Open Access

This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.




1. Calkins H, Reynolds MR, Spector P, et al., Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and metaanalyses, Circ Arrhythm Electrophysiol, 2009;2:349–61.
2. Spector P, Reynolds MR, Calkins H, Sondhi M, Xu Y, Martin A, Williams CJ, Sledge I, Meta-analysis of ablation of atrial flutter and supraventricular tachycardia, Am J Cardiol, 2009;104:671–7.
3. Sawhney N, Anousheh R, Chen WC, et al., Five-year outcomes after segmental pulmonary vein isolation for paroxysmal atrial fibrillation, Am J Cardiol, 2009;104:366–72.
4. Weerasooriya R, Khairy P, Litalien J, et al., Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?, J Am Coll Cardiol, 2011;57:160–6.
5. Ganesan AN, Shipp NJ, Brooks AG, et al., Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis, J Am Heart Assoc, 2013;2:e004549.
6. Macle L, Khairy P, Weerasooriya R, et al., Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial, Lancet, 2015;386:672–9.
7. Themistoclakis S, Schweikert RA, Saliba WI, et al., Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation, Heart Rhythm, 2008;5:679–85.
8. Joshi S, Choi AD, Kamath GS, et al., Prevalence, predictors, and prognosis of atrial fibrillation early after pulmonary vein isolation: findings from 3 months of continuous automatic ECG loop recordings, J Cardiovasc Electrophysiol, 2009;20:1089–94.
9. Koyama T, Tada H, Sekiguchi Y, et al., Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial, J Am Coll Cardiol, 2010;56:1463–72.
10. Oral H, Knight BP, Ozaydin M, et al., Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation, J Am Coll Cardiol, 2002;40:100–4.
11. O’Donnell D, Furniss SS, Dunuwille A, Bourke JP, Delayed cure despite early recurrence after pulmonary vein isolation for atrial fibrillation, Am J Cardiol, 2003;91:83–5.
12. Calkins H, Kuck KH, Cappato R, et al., 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design, Heart Rhythm, 2012;9:632–96.
13. Berkowitsch A, Greiss H, Vukajlovic D, et al., Usefulness of atrial fibrillation burden as a predictor for success of pulmonary vein isolation, Pacing Clin Electrophysiol, 2005;28:1292–301.
14. Bertaglia E, Stabile G, Senatore G, et al., Predictive value of early atrial tachyarrhythmias recurrence after circumferential anatomical pulmonary vein ablation, Pacing Clin Electrophysiol, 2005;28:366–71.
15. Andrade JG, Macle L, Khairy P, et al., Incidence and significance of early recurrences associated with different ablation strategies for AF: a STAR-AF substudy, J Cardiovasc Electrophysiol, 2012;23:1295–301.
16. Andrade JG, Khairy P, Verma A, et al., Early recurrence of atrial tachyarrhythmias following radiofrequency catheter ablation of atrial fibrillation, Pacing Clin Electrophysiol, 2012;35:106-16.
17. Lellouche N, Jais P, Nault I, et al., Early recurrences after atrial fibrillation ablation: prognostic value and effect of early reablation, J Cardiovasc Electrophysiol, 2008;19:599–605.
18. Pokushalov E, Romanov A, Corbucci G, et al., Use of an implantable monitor to detect arrhythmia recurrences and select patients for early repeat catheter ablation for atrial fibrillation: a pilot study, Circ Arrhythm Electrophysiol, 2011;4:823–31.
19. Tanno K, Kobayashi Y, Kurano K, et al., Histopathology of canine hearts subjected to catheter ablation using radiofrequency energy, Jpn Circ J, 1994;58:123–35.
20. Issac TT, Dokainish H, Lakkis NM, Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data, J Am Coll Cardiol, 2007;50:2021–8.
21. Pappone C, Santinelli V, Manguso F, et al., Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation, Circulation, 2004;109:327–34.
22. Hsieh MH, Chiou CW, Wen ZC, et al., Alterations of heart rate variability after radiofrequency catheter ablation of focal atrial fibrillation originating from pulmonary veins, Circulation, 1999;100:2237–43.
23. Fenelon G, Brugada P, Delayed effects of radiofrequency energy: mechanisms and clinical implications, Pacing Clin Electrophysiol, 1996;19:484–9.
24. Verma A, Kilicaslan F, Pisano E, et al., Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction, Circulation, 2005;112:627–35.
25. Callans DJ, Gerstenfeld EP, Dixit S, et al., Efficacy of repeat pulmonary vein isolation procedures in patients with recurrent atrial fibrillation, J Cardiovasc Electrophysiol, 2004;15:1050–5.
26. Nanthakumar K, Plumb VJ, Epstein AE, et al., Resumption of electrical conduction in previously isolated pulmonary veins: rationale for a different strategy?, Circulation, 2004;109:1226–9.
27. Aviles RJ, Martin DO, Apperson-Hansen C, et al., Inflammation as a risk factor for atrial fibrillation, Circulation, 2003;108:3006–10.
28. Lellouche N, Sacher F, Wright M, et al., Usefulness of C-reactive protein in predicting early and late recurrences after atrial fibrillation ablation, Europace, 2009;11:662–4.
29. Katritsis D, Hossein-Nia M, Anastasakis A, et al., Use of troponin-T concentration and kinase isoforms for quantitation of myocardial injury induced by radiofrequency catheter ablation, Eur Heart J, 1997;18:1007–13.
30. Lim HS, Schultz C, Dang J, et al., Time course of inflammation, myocardial injury, and prothrombotic response after radiofrequency catheter ablation for atrial fibrillation, Circ Arrhythm Electrophysiol, 2014;7:83–9.
31. Madrid AH, del Rey JM, Rubi J, et al., Biochemical markers and cardiac troponin I release after radiofrequency catheter ablation: approach to size of necrosis, Am Heart J, 1998;136:948–55.
32. Pokushalov E, Romanov A, Shugayev P, et al., Selective ganglionated plexi ablation for paroxysmal atrial fibrillation, Heart Rhythm, 2009;6:1257–64.
33. Lu Z, Scherlag BJ, Lin J, et al., Autonomic mechanism for initiation of rapid firing from atria and pulmonary veins: evidence by ablation of ganglionated plexi,
Cardiovasc Res, 2009;84:245–52.
34. Katritsis DG, Pokushalov E, Romanov A, et al., Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial, J Am Coll Cardiol, 2013;62:2318–25.
35. Pokushalov E, Romanov A, Katritsis DG, et al., Ganglionated plexus ablation vs linear ablation in patients undergoing pulmonary vein isolation for persistent/long-standing persistent atrial fibrillation: a randomized comparison, Heart Rhythm, 2013;10:1280–6.
36. Zhang Y, Wang Z, Zhang Y, et al., Efficacy of cardiac autonomic denervation for atrial fibrillation: a meta-analysis, J Cardiovasc Electrophysiol, 2012;23:592–600.
37. Huang SK, Graham AR, Wharton K, Radiofrequency catheter ablation of the left and right ventricles: anatomic and electrophysiologic observations, Pacing Clin Electrophysiol, 1988;11:449–59.
38. Wittkampf FH, Hauer RN, Robles de Medina EO, Control of radiofrequency lesion size by power regulation, Circulation, 1989;80:962–8.
39. Verma A, Mantovan R, Macle L, et al., Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial, Eur Heart J, 2010;31:1344–56.
40. Bertaglia E, Stabile G, Senatore G, et al., Long-term outcome of right and left atrial radiofrequency ablation in patients with persistent atrial fibrillation, Pacing Clin Electrophysiol, 2006;29:153–8.
41. Choi JI, Pak HN, Park JS, et al., Clinical significance of early recurrences of atrial tachycardia after atrial fibrillation ablation, J Cardiovasc Electrophysiol, 2010;21:1331–7.
42. Liang JJ, Elafros MA, Chik WW, et al., Early recurrence of atrial arrhythmias following pulmonary vein antral isolation: Timing and frequency of early recurrences predicts long-term ablation success, Heart Rhythm, 2015;12:2461–8.
43. Andrade JG, Khairy P, Macle L, et al., Incidence and significance of early recurrences of atrial fibrillation after cryoballoon ablation: insights from the multicenter Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP AF) Trial, Circ Arrhythm Electrophysiol, 2014;7:69–75.
44. Hernandez-Romero D, Marin F, Roldan V, et al., Comparative determination and monitoring of biomarkers of necrosis and myocardial remodeling between radiofrequency ablation and cryoablation, Pacing Clin Electrophysiol, 2013;36:31–6.
45. Khairy P, Chauvet P, Lehmann J, et al., Lower incidence of thrombus formation with cryoenergy versus radiofrequency catheter ablation, Circulation, 2003;107:2045–50.
46. Oswald H, Gardiwal A, Lissel C, Yu H, Klein G, Difference in humoral biomarkers for myocardial injury and inflammation in radiofrequency ablation versus cryoablation, Pacing Clin Electrophysiol, 2007;30:885–90.
47. Miyazaki S, Kuroi A, Hachiya H, et al., Early recurrence after pulmonary vein isolation of paroxysmal atrial fibrillation with different ablation technologies - prospective comparison of radiofrequency vs. second-generation cryoballoon ablation, Circ J, 2016;80:346–53.
48. Das M, Wynn GJ, Morgan M, et al., Recurrence of atrial tachyarrhythmia during the second month of the blanking period is associated with more extensive pulmonary vein reconnection at repeat electrophysiology study, irc Arrhythm Electrophysiol, 2015;8:846–52.
49. Kaleschke G, Hoffmann B, Drewitz I, et al., Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes, Europace, 2009;11:1362–8.
50. Reynolds MR, Walczak J, White SA, et al., Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs, Circ Cardiovasc Qual Outcomes, 2010;3:615–23.
51. Wokhlu A, Monahan KH, Hodge DO, et al., Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect, J Am Coll Cardiol, 2010;55:2308–16.

Further Resources

Share this Article
Related Content In Atrial Fibrillation
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72